Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
US9238690B2 · kind B2 · utility
0Cited by
58References
38Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 28, 2011 |
| Grant date | Jan 19, 2016 |
| Priority date | — |
| Expiry date | Oct 28, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/912
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.